leveraging neoadjuvant and adjuvant immunotherapy to improve outcomes in early-stage cancers
Published 2 years ago • 508 plays • Length 1:29:06Download video MP4
Download video MP3
Similar videos
-
52:29
improving outcomes in resectable nsclc: decisions about neoadjuvant and adjuvant immunotherapy
-
1:31:16
pathologic response after neoadjuvant immunotherapy: facilitating progress in early-stage cancers
-
3:02
neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer
-
59:58
management of esophageal/gej cancers: an interdisciplinary tumor board on adjuvant immunotherapy
-
1:35:31
leveraging targeted therapies to improve outcomes across the continuum of her2 breast cancer
-
27:18
adjuvant and neoadjuvant dilemmas
-
1:08:00
has immunotherapy brought us to an inflection point in the management of stage i-iii nsclc?
-
0:50
emerging role of adjuvant immunotherapy in oncology
-
1:26
dr. menter on neoadjuvant immunotherapy in early-stage nsclc
-
1:54
neoadjuvant immunotherapy improves outlook in high-risk melanoma
-
38:09
understanding and working with new immunotherapeutic and targeted management models in advanced rcc
-
1:01:58
essential conversations for hcc: radiology-oncology collaboration and immunotherapy advances
-
1:04:49
navigating multidisciplinary care with immunotherapy in esophageal/gej cancer
-
2:59
adjuvant and neoadjuvant immunotherapy in mcc
-
1:00:18
improving clinical care with newer better therapies for targeting actionable gene fusions in nsclc
-
47:59
the future of melanoma: what to anticipate in 2023 with neoadjuvant and adjuvant pembrolizumab
-
13:54
neoadjuvant therapy in melanoma
-
1:26:11
immunotherapy for the win against melanoma
-
1:11:32
refining best practices in cancer immunotherapy biomarker testing and pathologic response assessment